Updated Jul 21, 2026
/Parenting expert Reem Raouda identifies 7 habits in study of more than 200 parent-child pairs/Le Slip Français set for Paris stock market debut, testing whether local can outlast fast fashion/Wall Street set for $11 billion fee quarter as mega-mergers and SpaceX IPO lift dealmaking/Warsh's rate-signal silence puts hedge funds in the dark on Fed policy/B&R Technology Merger Corp. prices $325 million IPO on Nasdaq/Zions Bancorporation posts $452 million in Q2 2026 net earnings, $3.05 per diluted share/Parenting expert Reem Raouda identifies 7 habits in study of more than 200 parent-child pairs/Le Slip Français set for Paris stock market debut, testing whether local can outlast fast fashion/Wall Street set for $11 billion fee quarter as mega-mergers and SpaceX IPO lift dealmaking/Warsh's rate-signal silence puts hedge funds in the dark on Fed policy/B&R Technology Merger Corp. prices $325 million IPO on Nasdaq/Zions Bancorporation posts $452 million in Q2 2026 net earnings, $3.05 per diluted share
NewsSOS
← NewswireMarkets

Purcell & Lefkowitz opens shareholder probe into AN2 Therapeutics directors

NEW YORK, July 20. Purcell & Lefkowitz LLP disclosed Sunday it is investigating AN2 Therapeutics, Inc. (NASDAQ: ANTX) on behalf of the company's shareholders, with the inquiry focused on whether the biotech's directors breached their fiduciary duties. The New York law firm provided no further detail on what specific conduct or corporate action prompted the probe.

By Jonah Berg2 min read
Share

Key takeaways

  • Purcell & Lefkowitz LLP disclosed on Sunday, July 20, that it is investigating AN2 Therapeutics, Inc. (NASDAQ: ANTX) on behalf of the company's shareholders.
  • The probe focuses on whether AN2 Therapeutics's directors breached their fiduciary duties.
  • The New York law firm did not identify specific board members, transactions, or decisions under review.
  • No timeline for the investigation was provided in the firm's disclosure.
  • AN2 Therapeutics trades on the Nasdaq under the ticker symbol ANTX.

NEW YORK, July 20. Purcell & Lefkowitz LLP disclosed Sunday it is investigating AN2 Therapeutics, Inc. (NASDAQ: ANTX) on behalf of the company's shareholders, with the inquiry focused on whether the biotech's directors breached their fiduciary duties. The New York law firm provided no further detail on what specific conduct or corporate action prompted the probe.

The inquiry

The investigation centers on potential fiduciary duty breaches by AN2 Therapeutics's board of directors, according to the firm's announcement. Purcell & Lefkowitz did not identify specific board members by name or disclose which transactions or decisions are under review.

No timeline for the investigation was provided in the firm's disclosure.

AN2 Therapeutics

AN2 Therapeutics is listed on the Nasdaq under the ticker symbol ANTX. The firm's announcement stated the investigation is being conducted on behalf of ANTX shareholders.

Note: The source summary is limited. This article reports only the facts disclosed. No figures, transaction details, or additional context were available in the source material.

Keep reading

All bulletins →
MarketsJuly 21, 2026

Parenting expert Reem Raouda identifies 7 habits in study of more than 200 parent-child pairs

UNDATED. Seven habits, practiced early in a child's life, predict whether that child will confide in a parent as an adult, parenting expert Reem Raouda said, drawing on a study of more than 200 parent-child relationships. Raouda released the habits alongside her findings, describ

2 min read
MarketsJuly 21, 2026

Le Slip Français set for Paris stock market debut, testing whether local can outlast fast fashion

PARIS, July 21. Le Slip Français, a French underwear brand, is set to make its stock market debut in Paris on Tuesday, betting that consumers will pay for domestically manufactured clothing. The listing position

2 min read
MarketsJuly 21, 2026

Wall Street set for $11 billion fee quarter as mega-mergers and SpaceX IPO lift dealmaking

NEW YORK, July 21. About $11 billion in combined investment banking fees is expected from six large banks this quarter, as a resurgence in mega-mergers and the [SpaceX initial public offeri

2 min read

Frequently asked

Who is being investigated and by whom?

The New York law firm Purcell & Lefkowitz LLP is investigating AN2 Therapeutics, Inc. (NASDAQ: ANTX) on behalf of the company's shareholders.

What is the investigation about?

It centers on whether AN2 Therapeutics's board of directors breached their fiduciary duties.

Did the firm name specific directors or transactions?

No, Purcell & Lefkowitz did not identify specific board members by name or disclose which transactions or decisions are under review.

When was the investigation disclosed?

The firm disclosed the investigation on Sunday, July 20, from New York.

Was a timeline given for the investigation?

No timeline for the investigation was provided in the firm's disclosure.